Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ)

Technology #94019

The Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ) is a reliable and valid patient-oriented measure of the adverse effects of heart failure on a patient's life.

The United States Food and Drug Administration (FDA) has approved the Minnesota Living with Heart Failure Questionnaire as Medical Device Development Tool (MDDT) for use in controlled clinical trials designed to test superiority or non-inferiority of medical devices in support of regulatory submissions. The patient-reported outcomes can be used to determine whether a treatment for heart failure is effective for improving patients’ quality of life by reducing the adverse impact of heart failure.

License Required to use MLHFQ

A license from the University of Minnesota is required to use MLHFQ for any purpose. Purchase the license that best matches your intended use. Questionnaire and supporting materials available for download after online completion of license agreement and payment of fee.

MLHFQ Translations

The Questionnaire is available from the University of Minnesota in the English language version only.

Learn about more groundbreaking discoveries at www.research.umn.edu/ttechcomm
The MLHFQ license allows you to translate the Questionnaire without any further obligations to the University of Minnesota as long as all translations are used for the same study or protocol. Additional information on obtaining translations.

**Quality of Life Questionnaire - Scoring Criteria**

The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient’s life. After receiving brief standardized instructions, the patient marks a 0 (zero) to 5 scale to indicate how much each itemized adverse of heart failure has prevented the patient from living as he or she wanted to live during the past 4 weeks. The questionnaire is simply scored by summation of all 21 responses.

The instrument can be used as a key outcome measure in studies and evaluations of outpatients with symptomatic (NYHA class II to IV) heart failure with a reduced or preserved ejection fraction. This patient-reported outcome can be used to determine whether a treatment for heart failure is effective for improving patients’ quality of life by reducing the adverse impact of heart failure.

**MLHFQ Detailed Information**

More detailed information about the Minnesota Living with Heart Failure Questionnaire is available in the FDA MDDT Qualification Package. A license from the University of Minnesota is required before using the Questionnaire.

Please send your inquiries to **mlhfq@umn.edu**

**Inventors**

Thomas Rector
IP: UM Docket 94019

For additional information, contact

Guru Venkatesan  
Technology Commercialization Fellow  
exprlic@umn.edu  
612-301-2728

Learn about more groundbreaking discoveries at www.research.umn.edu/techcomm